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Induction of p53 protein by gamma radiation in lymphocyte lines from
breast cancer and ataxia telangiectasia patients
GW Birrell and JR Ramsay
Queensland Radiun Institute Research Laboratory, Queensland Institute ofMedical Research, Post Office Royal Brisbane
Hospital, Brisbane 4029, Australia
Sm y Exposure of human cells to '-tradiation causes levels of the tumour-suppressor nuclear protein p53
to increase temporal association with the icrease replctive DNA synthesi Cells from patients with the
radiosensitive and cancer-prone disease ataxia telangictasa (AT) exhibit radioresstant DNA synthesi and
show a reduced or delayed -yradiation-induced increase in p53 proten levels. We have used Western
immunoblotting with semiquantitative densitometry to examine the v-radiation-induced levels ofp53 protein in
57 lymphoblastoid cell ines (LCLs) derived from patients with AT, carriers of the AT gene, breast cancer
patients and normal donors. We confirm the previously reported reduced induction in AT homozygote LCLs
(n = 8) compared with normal donor LCLs (n = 17, P = 0.01). We report that AT heterozygote LCLs (n = 5)
also have a significantly reduced p53 induction when compared with LCls from normal donors (n = 17,
P = 0.02). The response of breast cancer patient cells was not sigmiicantly different from normal donor cells
but 18% (5/27) had a p53 response in the AT heterozygote range (95% confidence interval) compared with
only 6% (1/17) of the normal donor cells. We found no significant correlation between p53 induction and
cellular radiosensitivity in LCLs from breast cancer patients. These methods may be useful in identifying
individuals at greater risk of the DNA-damaging effects of ionising radiation.
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Exposure of mammalian cells to 7-radiation results in an
inhibition of replicative DNA synthesis and cell cycle arrest.
The arrest of cells in GI phase is accompanied by a concur-
rent increase in stable p53 protein. Cells that either lack p53
gene expression or overexpress a mutant form of p53 do not
exhibit a GI arret after 7-radiation (Kastan et al., 1991).
Kuerbitz et al. (1992) demonstrated that expression of wild-
type p53 causes the GI arrest after 7-radiation by (1) acquisi-
tion of the GI arrest following transfection of wild-type p53
genes into p53-deficient cells and (2) loss of the GI arrest
following transfection of mutant p53 genes into cells with
wild-type p53 genes. Cell cycle checkpoints presumably exist
to prevent replication of a damaged DNA template (GI
arrest) and segregation of damaged chromosomes (G2 arrest
Kastan et al., 1992). Delays at these checkpoints presumably
allow DNA repair before replicative DNA synthesis and
mitosis so that cellular survival is enhanced and the transmis-
sion of genetic errors reduced (Weinert and HartwelL 1988).
As well as cell cycle regulation, p53 has been implicated in
apoptosis, probably by means of transcriptional regulation
(Lane, 1994). Studies on human tumour cell lines expressing
mutant p53 have shown increased resistance to 7-radiation
(Mcllwrath et al., 1994) when compared with lines expressng
wild-type p53. They postulate that resistance may result from
the inability of the cells to undergo apoptosis. However,
others have failed to observe a correlation with p53 status
and radiosensitivity (Brachman et al., 1993).
Ataxia telangiectasia (AT) is a human autosomal recessive
disorder characterised by chromosomal instability, extreme
sensitivity to 7-radiation and a predisposition to cancer. Cells
from AT homozygotes show a reduced induction in p53
protein post 7-radiation compared with normal donor cells
(Kastan et al., 1992; Nasrin et al., 1994). Also, AT cells are
deficient in the GI arrest post radiation (Nagasawa and
Little, 1983) and demonstrate radioresistant DNA synthesis
(Houldsworth and Lavin, 1980). Lavin et al. (1992) showed
that AT heterozygotes can be identified by a greaer than
normal accumulation of LCLs in G2 phase 24 h post irradia-
tion using a fluorescence-activated cell analyser. This phase
delay was not observed in the G1 phase where the p53
protein is involved. We set out to measure p53 induction in
LCLs from breast cancer patients and to examine correlation
with cellular radiosensitivity.
LCLs from AT homozygotes show a deficient p53 induc-
tion in response to 7-radiation yet a normal response to UVB
radiation, an agent to which AT cells are not hypersensitive
(Khanna and Lavin, 1993). Nasrin et al. (1994) sequenced the
hypermutable exons (5-8) of germline p53 in fibroblasts
from three AT homozygotes. No mutations were found, yet
these cell lines demonstrated characteristic radioresistant
DNA synthesis and reduced induction of p53 protein post
7-radiation.
AT homozygotes have a 100-fold higher risk of cancer
than the general population (Swift et al., 1991) thus it is
possible that defective p53 induction is a key factor in their
cancer predisposition. In the present study, we have extended
the previous work to examine p53 induction in AT heter-
ozygotes. These comprise about 1-3% ofthe general popula-
tion and epidemiological studies suggest that they also have a
significantly increased risk of cancer (Peterson et al., 1992).
In partiular, females have been shown to have a 6.8-fold
increased risk ofdeveloping breast cancer (Swift et al., 1990).
Data on p53 induction in AT lines have been compared with
lines from breast cancer patients and normal females. Indi-
viduals with breast cancer were examined because of the
relationship to AT heterozygotes.
MNaeras an
Cell culture
The AT cells were obtained from Professor Martin Lavin.
Peripheral blood samples were obtained from normal female
donors and from breast cancer patients at least 6 months
after radiotherapy treatment at the Queensland Radium Ins-
titute. The 27 breast cancer patient LCLs included five from
patients who had experinced severe late effects from clinical
radiotherapy. These were included to examine correlation
between in vitro p53 induction and clinical radiosensitivity.
Of the 22 unselected breast cancer patients four had a first-
degree relative with breast cancer and this group was also
examined for anomalies in p53 induction.
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Lymphoblastoid cell lines (LCLs) were derived by Eps-
tein-Barr virus (EBV) transformation of peripheral blood
mononuclear cells (Neitzel, 1986). The LCLs were main-
tained in RPMI-1640 medium with 10% fetal bovine serum
(FBS) in a 5% carbon dioxide atmosphere at 3rC and were
found free of mycoplasma using the Hoechst 33258 stain.
Cultures in exponential growth phase were diluted in fresh
medium before radiation treatment.
Radiation treatment
LCL cultures were 7-radiated with 8 Gy using a caesium
source (Oris Industries, France, dose rate 3.0 Gy min-').
Equivalent cells were processed without radiation to assay
basal p53 protein levels. Samples were retured to a carbon
dioxide incubator for 5 h for the p53 protein to accumulate.
Whole cell lysates were prepared for p53 protein Western
blot analysis as follows. The LCLs were washed twice in cold
phosphate-buffered saline (PBS; 5 mM disodium hydrogen
phosphate, 3 mM potassium dihydrogen phosphate, 145 mM
sodium chloride, pH 7.2), cell counts performed and cells
transferred to microfuge tubes. Cells were lysed in lysis buffer
(10mM Tris pH 7.2, 20% glyceroL 1% sodium dodecyl sul-
phate, 10mM dithiothreitoL 1 mM phenylmethylsulphonyl
fluoride) to 2.5 x 10' cell equivalents per microlitre. The
pellets were solubilised by brief sonication at 4-C (Branson
Sonifler Model 250). Total protein was dermined using a
protein assay kit (Pierce, IL, USA). Samples were stored at
-770C before assay.
Gel electrophoresis and Western blotting
Aliquots (20 p1) of each sample representing 5 x IOW cells
were separated by SDS-PAGE on a 10% polyacrylamide gel
using a mini-gel system (Bio-Rad, CA, USA). Molcular
weight markers (Bio-Rad) and a positive control were run on
each gel. The positive control consiste of 20 11 (5 x I05 cell
equivalents) of a known positive LCL preprued as described
above and aliquoted for inclusion in each gel. To compare
LCLs assayed on different blots, it was necessary to inlude a
positive control in each blot to normalis the sample values.
A pool of cell lysates from an irradiated normal donor LCL
prepared as above was aliquoted and used as the positive
control. The densitometric scan value of the positive control
was assigned a value of 1 with the values of the other
samples on the same blot adjusted proportionally.
After electrophoresis, proteins were transferred to nitrocel-
lulose membranes (Schkeicher and Schuell, Germany) in
transfer buffer [25 mM Tris, 192 mm glycine, 20% (v/v)
methanol pH8.31. The membranes were stained with
Ponceau red (Sigma, St Louis, MO, USA) to determine
protein loading. The membranes were blocked overnight in
5% skmmed milkl and incubated for 2 h in anti-p53 protein
monoclonal antibody; PAb 1801 (NovoCastra, Newcastle,
UK) diluted in PBS/Tween 20, (PBS, 0.05% Tween 20,
pH 72). Membranes were washed five times in PBS/Tween
between each incubation. AlIkaline phosphatase conjugated
anti-mouse Ig (Silenus, Hawthorne Vic.) in PBS/Tween was
used as the secondary antibody and the p53-specific band
was visuased by a 15 min incubation in the substrates 5-
bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue
tetrazolium (NBT). Substrate development was stopped by
immersing the membranes in water. Membranes were scan-
ned on a laser densitometer (Molecular Dynamics, CA, USA)
at 488 nm and p53 protein bands quantified using Image
Quant software (Molecular Dynamics) according to the
manufacturer's instructions.
MIT assay ofcell killing
The MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium)-based colorimetric growth assay (Mossman, 1983) was
used for the estimation of cellular radiosensitivity and is
described in detail elswhere (Ramsay and Birrel, 1995).
Briefly, confluent, viable cells are irradiated to various doses
(0, 0.5, 1 and 2Gy) and plated into quadruplicate wells of
replcate 96-well microplates. After 5 and 7 days post irradia-
tion, the MTT reagent is added at 500iLgml-' and the
microplates reincubated for 4 h to allow mitochondrial
enzymes to reduce the MTI to a coloured insoluble for-
mazan product. After formazan solubilisation in dimethyl
sulphoxide (DMSO) the microplates are analysed using a
multi-well spectrophotometer and surviving fractions cal-
culated.
Statistical analysis
Analysis of statistical significance was determined using
Student's two-tailed t-test. Confidence limits of 95% were
determined using Sigmaplot Scientific Graphing Software
(Jandel, CA, USA).
Clinical information
Records of individuals with breast cancer were examined for
age, family history of cancer and adverse reaction to
radiotherapy. They were assessed on the Radiation Therapy
Oncology Group (RTOG) scoring scheme for late effects
(Ramsay and Birrell, 1995).
Resdts
Time, dose and linearity ofresponse
A preliminary experiment of the effect of cell growth on
radiation-induced p53 protein expression showed an approx-
imately 2-fold higher induction in irradiated cells from an
exponential culture when compared with irradiated cells from
a stationary phase culture of the same normal donor LCL
(Table I). Exponential cultures were used throughout this
study.
Preliminary assays of time and dose response to
radiation treatment were performed on a normal donor LCL
and AT LCLs. In the dose response, the normal LCL
showed maximal p53 induction after 8 Gy while the AT line
showed a much lower response. In the time course
experiments, the normal donor showed a rapid induction up
to 5 h then a fall-off down to basal levels by 24 h. For the
AT LCLs, there was a small increase in p53 in groups A and
D which again fell off by 24h. One AT LCL (group E)
showed a siilar increase in p53 levels to the normal but the
response was delayed (Figure lb). From these initial
experiments, a 5 h incubation before cell harvest (Figure la)
after a dose of 8 Gy (Figure lb) was chosen as suitable by
maximum dicimination between the two and subsequently
used for all LCLs.
To determine the linearity of response, dilutions of the
positive control cell lysate were Western blotted and den-
sitometrically scanned as described. A linear response was
found to occur in the range of 1 x 105-6 x105 cell
equivalents which corresponded to 20 zg total protein per 105
cells. In this study, 5 x 105 cell equivalents were assayed for
all sampks.
Reproducibility ofassay
To assess the variation in p53 induction in LCLs from an
individual, three blood samples were taken from a normal
donor from which three separate LCLs were estabished and
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Flgwe 1 (a) Dose-response curves for a normal donor and an
AT LCL. Cultures were treated with different doses of'-tradiation
and harvested after 5 h. Cell lysates were separated by 10%
SDS-PAGE, terrd to nitrocllulose and immunoblotted
with anti-p53 monodonal antibody (PAb 1801). The p53-specific
bands were quantified using a sanning laser densitometer
(488 nm) and associated software. *, Normal donor LCL; 0,
AT LCL (group E). (b) Time-response curves for a normal donor
and three AT LCLs. Cultures were treated with 8 Gy -t-radiation
and reincubated for different time periods before harvest Cell
lysates were prepared and assayed as above. *, Normal donor
LCL; 0, AT LCL (group E); 0, AT LCL (group D); A, AT
LCL (group A). Error bars are standard error of the mean from
three experments.
assayed. The coefficient of variation (CV) was found to be
7.8%. Three aliquots of the same cell lysate were assayed
together and the intra-assay CV was found to be 1%.. An
internal positive control was incuded in each assay which
was used to normalise other sample values. Three assays were
performed on separate cultures of LCLs from 17 normal
donors, five AT heterozygotes and eight AT homozygotes.
The 27 breast cancer patient LCLs were assayed once.
Cellgrowth effects
To examine the effects of cell growth on p53 induction, a
normal donor LCL was examined from both a log-phase
culture and a stationary-phase culture. The stationary-phase
culture was induced by not changing culture media for 5 days
whereas the log-phase culture resulted from changing culture
media three times a week. The difference between the two
cultures was confirmed using flow cytometry (FACScan, Bec-
ton Dickinson) ofpropidium iodide-stained LCLs. Cells from
both cultures were '-tradiated (0 and 8 Gy) and reincubated
for 5 h for p53 protein to accumulate. Cell lysates were
prepared and assayed as above. A 2-fold greater increase in
induced p53 protein was observed in the exponential culture
compared with the stationary culture (Table I). Only
exponential cultures were used in this study.
pS3 induction in normal donor, ATandbreast cancer LCDs
A representative p53 Western blot which includes treated and
untreated LCL lysates from an AT heterozygote, an AT
homozygote (group A) and a normal donor is shown as
Figure 2. The relative levels of induced p53 protein (level
induced 5 h after 8 Gy minus unirradiated levels) for all
LCLs are shown in Figure 3. The normal donor LCLs
showed a 6-fold range of induction and all demonstrated a
substantial increase post irradiation. One of the normal
donor LCLs had a normal basal level yet a very high induced
p53 response on three separate occasions. This may be due to
increased production or enhanced protein stability. The eight
homozygote LCLs included four LCLs whose complmenta-
tion group was known. These cultures were from comp-
klmentation groups A, C, D and E. All these complementa-
tion groups demonstrated reduced p53 induction in com-
parison with the mean normal donor response 5 h post
irradiation. The group E LCL showed the highest induction
(0.52) followed by groups C (0.39), D (0.26) and A (0.11). A
6-fold variation induction was observed in the AT
homozygote LCLs. Basal and p-yradiation-induced p53 pro-
tein levels from all LCLs are sunmnarised in Table H. When
analysed as groups, both the AT homozygote and AT
heterozygote LCLs demonstrated significantly reduced lkvels
of p53 protein induction compared with the normal donors
(P = 0.01 and P = 0.02 respectively). The AT heterozygotes
formed a narrow range intermediate in response between the
AT homozygotes and the normal donors.
The mean response in the breast cancer LCLs was not
significantly different from the normal donors (P = 0.4), but
5/27 (18%) had relatively low levels of p53 induction which
was in the AT heterozygote range (95% confidence limits).
For the normal donor LCLs, only 1/17 (6%) was within the
AT range.
Relationship to radiosensitivity
We have previously reported on variations in radiosensitivity
in LCLs derived from breast cancer patients using the MTT
assay (Ramsay and Birrell, 1995). Patients who developed
complications from radiotherapy were found to be
significanty more sensitive. Direct comparison was made
between radiosensitivity as measured by surviving fraction at
2 Gy and levels of p53 induction in the 27 assessable breast
cancer patients. The data are plotted in Figure 4 and there is
no correlation between the two parameters.
1 2 3 4 5 6 7 8
11mv 2 p53 inunuoblot. Cells were treated ± 8 Gy p-radiation
and reincubated for 5 h before harvestig. Cell lysates were run
on 10% polyacrylamide gels, transferred to nitroceluose and
p53-specific band identified using a monoclonal £-p53 antibody
(PAb 1801) and visualised ugsin the substrates BCIP and NBT.
Lane 1, AT heterozygote OGy; lane 2, AT heterozygote 8 Gy;
lane 3, AT LCL 0Gy; lane 4, AT LCL 8 Gy; lane 5, normal
donor LCL 0 Gy-, lane 6, normal donor LCL 8 Gy, lane 7,
positive control; lane 8, molecular weight markers (180, 125, 88,
65, 56, 38, 33.5 kDa).G6_ralaI ducis d p53 inlympoccel ed
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Fge 3 Induced p53 protein levels from LCLs for eight AT
homozygotes, five AT heterozygotes, 17 normal donors and 27
breast cancer patients. Data points represent the mean value from
three separate experiments on all but breast cancer LCLs which
were assayed once only.
Relationship to clinicalfactors
Late reaction to clinical radiotherapy was assessed using the
RTOG scoring scheme in 17 of the 27 breast cancer patients
at least 2 years after radiotherapy for primary breast cancer.
Five of these individuals were judged to have suffered severe
late reactions (Grade 3 or 4) to skin and subcutaneous tissue
in the irradiated area. Two of the five showed a markedly
deficient response (levels 0.15 and 0.30) but the remaining
three showed p53 induction within the normal range.
Similarly, the three other individuals with low p53 induction
showed normal response to radiotherapy. This data would
suggest that this assay would have a low probability of
predicting clinical radiosensitivity. Four of the breast cancer
patient LCLs were from individuals with family histories of
cancer. All four had basal p53 levels within the normal range
and showed a p53 response to 7-radiation also within the
normal range. No correlation was observed between patient
age and p53 induction (data not shown).
Dission
The -tradiation-induced and basal levels of p53 protein in 57
lymphoblastoid cell lines were assessed using Western blot-
ting with scanning densitometry. The monoclonal antibody
used, PAb 1801, reacts with a 47 amino acid region localised
to the amino terminus (Ullrich et al., 1992) and detects both
wild-type and mutant forms of p53 protein. Wild-type p53
protein has a short half-life (Oren et al., 1981; Finlay et al.,
1988), yet agents which cause DNA damage, including 7-
radiation, cause an accumulation of p53 protein in normal
cells. The accumulation is due to increased protein stability
Fugwe 4 Induced p53 protein levels plotted against in vitro
radiosensitivity (surviving fraction at 2 Gy) for the breast cancer
LCLs. 0, Breast cancer patient LCLs; *, AT homozygote LCL;
0, AT heterozygote LCL. Induced p53 protein was determined
by quantitative immunoblotting as described above and
represents the means of three experiments. Surviving fractions at
2 Gy are the means of three experiments using the MTT col-
orimetric growth assay.
resulting from a post-transcriptional mechanism (Kastan et
al., 1991). Pulse chase labelling experiments using 35S
methionine confirm p53 protein stability after DNA damage
(Fritsche et al., 1993; Liu et al., 1994). Some cell lines
expressing mutant p53 protein have been shown to have high
basal p53 protein levels (Mcllwrath et al., 1994). Low basal
levels of p53 were observed in all 57 LCLs assayed, sugges-
ting the p53 protein detected in these cells was probably
wild-type. Cells that lack p53 expression or express a mutant
protein, can fail to arrest in GI post 7-radiation, however the
G2 arrest is unaffected by p53 status (Kastan et al., 1991).
The inhibition of replicative DNA synthesis after DNA
damage may be important in avoiding the increase in
genomic changes that characterise tumorigenesis by allowing
the cell to initiate either repair or apoptosis.
LCLs from AT homozygotes show a deficient p53 induc-
tion in response to 7-radiation yet a normal response to UVB
radiation, an agent to which AT cells are not hypersensitive
(Khanna and Lavin, 1993). Nelson and Kastan (1994) dem-
onstrated that DNA strand breaks are required for p53
induction. They also proposed that the AT gene product(s)
are upstream of p53 induction and may be involved in
responses to only certain types of strand breaks such as those
initiated by ionising radiation. In this study we have
confirmed the reduced levels of p53 induction in AT
homozygote cell lines as previously described (Kastan et al.,
1992). We have also shown a significant reduction in levels
from AT heterozygotes which may be relevant to their cancer
predisposition. Both normal donor and breast cancer LCLs
demonstrated a wide range in levels of induced p53. Some of
the breast cancer patients showing low levels may be related
Table H
Integrated O)
LCL No irradiation 8 Gy irradiation 8-0 Gy
AT homozygotes (n = 8) 0.034 (0.035) 0.303 (0.166) 0.269
AT heterozygotes (n = 5) 0.021 (0.015) 0.347 (0.049) 0.327
Normal donors (n = 17) 0.047 (0.027) 0.782 (0.376) 0.735
Breast cancer patients (n = 27) 0.052 (0.025) 0.636 (0.240) 0.584
'Mean integrated OD (488nm) values from densitometric scans of p53
immunoblots normalised to positive control internal standard. Three separate
assays were performed on all LCLs except those from breast cancer patients.
Values in brackets are standard deviations.
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to an increased proportion of AT heterozygotes reported to
occur in the breast cancer population (Easton, 1994).
Epidemiological studies have suggested that between 5% and
18% of all breast cancer patients may be AT beterozygotes
(Swift et al., 1991; Swift, 1994), although confirmation will
have to await the cloning of the AT gene(s). In view of the
importance of p53 in tumorigenesis, it is possible that
induced levels of p53 may be seen in other cancer-prone
genetic disorders.
Other methods have been used to identify AT
heterozygotes, including assays of cellular radiosensitivity
(Chen et al., 1978; Weeks et al., 1991), cytogenetic analysis
(Parshad et al., 1985) and assays ofcell cycle anomalie post
irradiation (Lavin et al., 1992; Peterson et al., 1992). In the
study by Weeks et al. (1991), the colony-forming ability after
low-dose-rate irradiation was measured in fibroblasts from
AT homozygotes, AT heterozygotes and normal donors.
They conclude that overlap in values between AT
heterozygotes and normls precludes the use of the assay for
the accurate identification of heterozygotes. Similarly, in the
present study we observed a significnt difference in p53
protein induction between these two groups but overlap prec-
ludes the use of the assay for AT heterozygote identification.
Parshad et al. (1985) found that fibroblasts from AT
heterozygotes, ike AT homozygotes, show a significntly
higher frequency of chromatid breaks and gaps than normal
controls using doses up to 1 Gy. Flow cytometric cell cycle
analysis ofAT LCLs has demonstrated a higher than normal
accumulation ofcells in G2 phase, 24 h after 3 Gy -tradiation
(Lavin et al., 1992). This flow cytometry assay showed
similar results to the Western blot assay in the present stuy
with AT heterozygotes forming a group intermediate in res-
ponse between normal donors and AT homozygotes. Lavin
et al. (1994) also showed that 20% of breast cancer LCLs
compared with 8% of normal donor LCLS have a G2 phase
arrest in the AT heterozygote range. We plan to assay breast
cancer LCLs using both the G2 phase delay assay and p53
induction post ?-radiation to examine for correlation between
the two parameters.
Scott et al. (1994) used an assay of radiation-induced
chromosome damage in lymphocytes in an attempt to iden-
tify AT heterozygotes in women with breast cancer. The
assay was a modification of that described by Sandford and
Parshad (1990) who show that sensitivity to radiation-
induced chromosome damag in G2 cells is strongly
associated with inherited cancer predisposition. In a series of
50 patients 21 (42%) had a chromosomal radiosensitivity in
the AT heterozygote range compared with 7/74 (9%) of
control donors. These values are higher than those esimated
for AT heterozygotes in either group (Easton, 1994).
SV40 transformation of human skin fibroblasts has been
shown to cause an increase in -radiation rsstance and
increased production of p53 mRNA when compared with
primary cell cultures (Luckehuhle, 1994). We have no
evidence for similar changes to lymphoid cells when trans-
formed with EBV. Mitogen-stimulated peripheral blood lym-
phocytes will grow and divide in cell culture for several
passages only. EBV-transformed lymphocytes will grow
indefinitely in culture but may undergo genetic changes after
extended periods in culture. Thus we endeavoured to use
early passage number LCLs and ensured the LCLs had
diploid DNA content by using flow cytometry of propidium
iodide-stained cultures (data not shown).
In summary, the Western blot assay described here demon-
strates significant differences in the -tradiation-induced p53
response between normal donors, AT heterozygotes and AT
homozygotes. A deficient p53 response to -tradiation may
not be due to AT heterozygosity. Other anomalies may also
result in deficient p53 protein induction. When mutant p53 is
expressed, cells may fail to arrest in GI post v-radiation. It
has been postulated that p53 mutations may be associated
with tumorigenesis. Thus a deficient p53 response to ^-
radiation may in some cases be an indicator of genomic
instability.
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